Pharmafile Logo
Pharmafocus logo
Advanced Search

melanoma

Showing 15 posts of 84 posts found.

Merck image

Merck’s melanoma vaccine impresses

November 19, 2013
Research and Development, Sales and Marketing MK-3475, Merck, Roche, melanoma

Merck has posted impressive results for its new melanoma vaccine MK-3475 as it looks to vie for a place in …

News
gsk_hq_close

GSK’s Tafinlar/Mekinist combo given FDA priority review status

September 17, 2013
Research and Development, Sales and Marketing GSK, Roche, Tafinlar, Zelboraf, melanoma

News
bms

Yervoy setback in prostate cancer

September 16, 2013
Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer

News
GSK image

GSK cancer vaccine fails in Phase III

September 5, 2013
Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III

GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …

News
Tafinlar image

GSK’s skin cancer pill Tafinlar gets EMA approval

September 3, 2013
Sales and Marketing BMS, GSK, Tafinlar, Yervoy, melanoma

GSK has been granted EMA marketing authorisation for its new metastatic melanoma drug Tafinlar. The EMA’s decision on Tafinlar (dabrafenib) …

News

Skin cancer death 70% more likely in men than women

August 23, 2013
Sales and Marketing CRUK, melanoma, skin cancer

News
Vical image

Vical melanoma drug dropped

August 13, 2013
Research and Development, Sales and Marketing Vical, allovectin, melanoma

Vical has abandoned trials of a late-stage drug for the deadliest form of skin cancer after the treatment failed to …

News
Zelboraf image

Eight in ten survive skin cancer

July 22, 2013
Research and Development, Sales and Marketing Yervoy, Zelboraf, melanoma, skin cancer

The vast majority of men and women diagnosed with malignant melanoma are now surviving the disease, according to a new …

News
FDA image

FDA seeks manufacturing data for GSK’s trametinib

May 2, 2013
Manufacturing and Production FDA, GSK, melanoma

GlaxoSmithKline’s melanoma drug candidate trametinib has been delayed in the US by an FDA request for more information on its …

News
Merck image

Melanoma breakthrough for Merck

April 26, 2013
Research and Development, Sales and Marketing FDA, Merck, lambrolizumab, melanoma

Merck’s pipeline has been given a boost by an FDA decision to designate early-stage investigational drug lambrolizumab as a breakthrough …

News
GSK image

GSK submits melanoma drugs for regulatory approval

August 3, 2012
Sales and Marketing FDA, GSK, NDA, Zelboraf, melanoma, oncology

GlaxoSmithKline has submitted its two investigational melanoma drugs to regulators in both Europe and the US. The firm is seeking …

News
Zelboraf image

Roche’s Zelboraf rejected by NICE

June 15, 2012
Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma

NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …

News

GSK starts combination trial for melanoma

May 30, 2012
Research and Development, Sales and Marketing GSK, R&D, Roche, Zelboraf, melanoma

GlaxoSmithKline has begun a combination trial for two of its investigational skin cancer drugs.  The firm will combine dabrafenib, its …

News
yervoy image

Scottish watchdog rejects Yervoy

May 14, 2012
Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma

The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy.  The SMC said that Yervoy (ipilimumab), which has …

News
Zelboraf image

European approval for Roche’s Zelboraf

February 20, 2012
Sales and Marketing Cancer, Roche, Yervoy, Zelboraf, melanoma

Roche’s skin cancer pill Zelboraf has been given European approval to treat advanced melanoma.  Zelboraf (vemurafenib) is now available in …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026